Bahar Akkaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bahar Akkaya has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ceren Hangül
Department of Medical Biology and Genetics, Faculty of Medicine, Akdeniz University, Antalya, Turkiye
1 shared publication - Demet Etit
Acibadem Maslak Hospital
1 shared publication - Emre Çağatay Köse
Department of Medical Pathology, Mersin University School of Medicine, Mersin, Turkey
1 shared publication - Erdem Akbay
Department of Urology, Faculty of Medicine, Mersin University, Mersin, Turkey
1 shared publication - Ferah Tuncel
Department of Pathology, Faculty of Medicine, Mersin University, 33110 Mersin, Türkiye
1 shared publication - Gul Emek Yuksek Wymer
Department of Pathology and Laboratory Medicine, HCA Florida Westside Hospital, Plantation, Florida, USA, lhsc.on.ca
1 shared publication
Latest Publications
- 1 January 2020
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 46 (4) , 282-287
The role of COL6A1and PD-1 expressions in renal cell carcinoma
Objective: The COL6A1 is a gene encoding the alpha 1 polypeptide subunit of collagen 6 (COL6A1), an extracellular matrix protein subunit. Programmed cell death receptor-1 (PD-1) and its ligand, programmed cell death receptor ligand-1 (PD-L1) have been shown to have a prognostic significance in clear cell renal cell carcinomas (RCCs). In this study, we evaluated the expressions of COL6A1 and PD-1 in four different RCC subtypes. Materials and methods: A total of 161 radical nephrectomy and nephron-sparing surgery cases with RCCs from five different health care centers were included in this study. Clinical data of the cases were taken from electronic records of the institutions. The pathological data were collected by an expert uropathologist and re-evaluated with slides obtained from paraffin blocks of the cases. The correlation of COL6A1 and PD-1 expression with sex, age, tumor type, lymphovascular invasion (LVI), World Health Organization/International Society of Urological Pathology (WHO/ISUP) grade, and tumor stage (pT) was analyzed with the Pearson chi-squared test. Results: Patients with sarcomatoid RCC and clear cell RCC had significantly higher COL6A1 scores and intensities than in other types of RCC (p=0.004 and p=0.002, respectively). WHO/ISUP grade and, COL6A1 and PD-1 staining scores also showed positive correlation (r=0.230, p=0.004 and r=0.277, p=0.001, respectively for COL6A1 and r=0.191, p=0.018 and r=0.166, p=0.041, respectively for PD-1). The staining scores and intensities of COL6A1 and PD-1 were not different between the patients with positive and negative LVI (p>0.05). Conclusion: In high-grade RCCs, we found the relationship between immunohistochemical staining scores of COL6A1 and PD-1 proteins and clinical, demographic, and histopathological parameters. Our results proved that COL6A1 and PD-1 are really promising proteins as prognostic parameters and for targeted immunotherapy. Cite this article as: Yuyucu Karabulut Y, Köse EÇ, Bozlu M, Tuncel F, Emek Yüksek G, Etit D, et al. The role of COL6A1and PD-1 expressions in renal cell carcinoma. Turk J Urol 2020; 46(4): 282-7.
- 1 January 2020
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 46 (4) , 282-287
The role of COL6A1and PD-1 expressions in renal cell carcinoma
Objective: The COL6A1 is a gene encoding the alpha 1 polypeptide subunit of collagen 6 (COL6A1), an extracellular matrix protein subunit. Programmed cell death receptor-1 (PD-1) and its ligand, programmed cell death receptor ligand-1 (PD-L1) have been shown to have a prognostic significance in clear cell renal cell carcinomas (RCCs). In this study, we evaluated the expressions of COL6A1 and PD-1 in four different RCC subtypes. Materials and methods: A total of 161 radical nephrectomy and nephron-sparing surgery cases with RCCs from five different health care centers were included in this study. Clinical data of the cases were taken from electronic records of the institutions. The pathological data were collected by an expert uropathologist and re-evaluated with slides obtained from paraffin blocks of the cases. The correlation of COL6A1 and PD-1 expression with sex, age, tumor type, lymphovascular invasion (LVI), World Health Organization/International Society of Urological Pathology (WHO/ISUP) grade, and tumor stage (pT) was analyzed with the Pearson chi-squared test. Results: Patients with sarcomatoid RCC and clear cell RCC had significantly higher COL6A1 scores and intensities than in other types of RCC (p=0.004 and p=0.002, respectively). WHO/ISUP grade and, COL6A1 and PD-1 staining scores also showed positive correlation (r=0.230, p=0.004 and r=0.277, p=0.001, respectively for COL6A1 and r=0.191, p=0.018 and r=0.166, p=0.041, respectively for PD-1). The staining scores and intensities of COL6A1 and PD-1 were not different between the patients with positive and negative LVI (p>0.05). Conclusion: In high-grade RCCs, we found the relationship between immunohistochemical staining scores of COL6A1 and PD-1 proteins and clinical, demographic, and histopathological parameters. Our results proved that COL6A1 and PD-1 are really promising proteins as prognostic parameters and for targeted immunotherapy. Cite this article as: Yuyucu Karabulut Y, Köse EÇ, Bozlu M, Tuncel F, Emek Yüksek G, Etit D, et al. The role of COL6A1and PD-1 expressions in renal cell carcinoma. Turk J Urol 2020; 46(4): 282-7.
- Open Access
- 3 May 2019
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 36 (2) , 125
The Coexistence of Chronic Lymphocytic Leukemia and Multiple Myeloma
- 3 May 2019
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 36 (2) , 125
Open AccessThe Coexistence of Chronic Lymphocytic Leukemia and Multiple Myeloma